A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high despite medication, according to the results of a Phase III clinical trial. 

The international BaxHTN trial, led by Professor Bryan Williams, UCL Institute of Cardiovascular Science, and sponsored by AstraZeneca, assessed the new drug baxdrostat – which is taken as a tablet – with participation from nearly 800 patients across 214 clinics worldwide.  

The study was supported by the NIHR Biomedical Research Centre at UCLH. Results were presented at the European Society of Cardiology (ESC) Congress 2025 in Madrid. 

The trial results showed that, after 12 weeks, patients taking baxdrostat (1mg or 2mg once daily in pill form) saw their blood pressure fall by around 9-10mmHg more than placebo – a reduction large enough to cut cardiovascular risk.  

About four in 10 patients reached healthy blood pressure levels, compared with fewer than two in 10 on placebo. 

Principal Investigator, Professor Williams, who is presenting the results at ESC, said: “Achieving a nearly 10mmHg reduction in systolic blood pressure with baxdrostat in the BaxHTN Phase III trial is exciting, as this level of reduction is linked to substantially lower risk of heart attack, stroke, heart failure and kidney disease.” 

Blocking aldosterone production 

Blood pressure is strongly influenced by a hormone called aldosterone, which helps the kidneys regulate salt and water balance. Some people produce too much aldosterone, which pushes blood pressure up and makes it very difficult to control. 

Baxdrostat works by blocking aldosterone production, directly addressing this driver of high blood pressure (hypertension). 

Professor Williams, Chair of Medicine at UCL, said: “These findings are an important advance in treatment and in our understanding of the cause of difficult to control blood pressure. Around half of people treated for hypertension do not have it controlled, however this is a conservative estimate and the number is likely higher, especially as the target blood pressure we try to reach is now much lower than it was previously. 

“This suggests that aldosterone is playing an important role in causing difficult to control blood pressure in millions of patients and offers hope for more effective treatment in the future.”